See more : Bendigo and Adelaide Bank Limited (BEN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NEONC TECHNOLOGIES HOLDINGS, INC., a leading company in the Biotechnology industry within the Healthcare sector.
- Garuda Construction and Engineering Limited (GARUDA.BO) Income Statement Analysis – Financial Results
- Stanley Black & Decker, Inc. (0L9E.L) Income Statement Analysis – Financial Results
- Zevia PBC (ZVIA) Income Statement Analysis – Financial Results
- Mitsui E&S Holdings Co., Ltd. (7003.T) Income Statement Analysis – Financial Results
- Caerus Mineral Resources Plc (CMRS.L) Income Statement Analysis – Financial Results
Neonc Technologies Holdings, Inc. (NTHI)
About Neonc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week
U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline
Source: https://incomestatements.info
Category: Stock Reports